Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes

BACKGROUND: Metastatic prostate cancer (CaP) treatments are evolving rapidly but without evidence-based biomarkers to predict responses, and to maximize remissions and survival. OBJECTIVE: To determine the activity of androgen receptor (AR), the target for default first-line systemic treatment, in l...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben-Salem, Salma, Hu, Qiang, Liu, Yang, Alshalalfa, Mohammed, Zhao, Xin, Wang, Irene, Venkadakrishnan, Varadha Balaji, Senapati, Dhirodatta, Kumari, Sangeeta, Liu, Deli, Sboner, Andrea, Barbieri, Christopher E., Feng, Felix, Billaud, Jean-Noel, Davicioni, Elai, Liu, Song, Heemers, Hannelore V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723342/
https://www.ncbi.nlm.nih.gov/pubmed/33299986
http://dx.doi.org/10.1016/j.euros.2020.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723342/
https://www.ncbi.nlm.nih.gov/pubmed/33299986
http://dx.doi.org/10.1016/j.euros.2020.10.002

Ejemplares similares